OncoMatch/Clinical Trials/NCT06345079
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Is NCT06345079 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cessation of somatostatin analogues and Continuation of somatostatin analogues for neuroendocrine tumors.
Treatment: Cessation of somatostatin analogues · Continuation of somatostatin analogues — Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not. The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: somatostatin analogue (octreotide, lanreotide) — growth-controlling doses for at least 12 weeks prior to study entry (minimum 30 mg octreotide or 120 mg lanreotide monthly)
Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study entry. This is a minimum of 30 mg Octreotide or 120mg lanreotide monthly. ...demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT
Cannot have received: chemotherapy
Prior chemotherapy or targeted therapy (e.g., everolimus)
Cannot have received: targeted therapy (everolimus)
Prior chemotherapy or targeted therapy (e.g., everolimus)
Cannot have received: peptide receptor radionuclide therapy
Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible
Lab requirements
Blood counts
adequate haematologic function as judged by the treating team
Kidney function
adequate renal function as judged by the treating team
Liver function
adequate hepatic function as judged by the treating team
Adequate renal, hepatic and haematologic function as judged by the treating team
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify